Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
RCT (n=152) reports cefiderocol, a novel siderophore cephalosporin antibiotic, had similar clinical and microbiological efficacy to best available therapy (pre-specified before randomisation and maximum of three drugs) in this population.
Source:
The Lancet Infectious Diseases
SPS commentary:
Authors’ of a related commentary state the global public health crisis of multidrug-resistant Gram-negative organisms underscores the need for antibiotics with novel bacterial targets such as cefiderocol, the first siderophore-conjugated antibiotic, designed to overcome challenges presented by common carbapenem-resistance mechanisms. This commentary also discusses results of a related non-inferiority study published in the same issue; which suggests cefiderocol may also be a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.
Cefiderocol is licenced in the UK for treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.